98 (27.8%) of 353 patients who had been biopsied for the ﬁrst time after PSA from 2.5 to 4, were diagnosed of prostate cancer. The percentage of positive cores in the sam- ple was of 31.5%. A signiﬁcant 43.8% of biopsies Gleason score were high. Conclusions: There are a signiﬁcant per- centage of patients with prostate cancer in the biopsy with PSA between 2.5-4ng/ ml, 27.8% on this study. In selected pa- tients, with more life expectance, our data suggest that will be advisable to pro- pose biopsies on this rate of PSA. MP-11.08 Reduced inﬁltration of macrophage scavenger receptor is associated with poor prognosis of prostate cancer Takayama H, Nonomura N, Nagahara A, Oka D, Nakai Y, Shiba M, Nakayama M, Nishimura K, Okuyama A Osaka University Graduate School Of Medicine, Osaka, Japan Introduction: The macrophage scavenger receptor 1 (MSR 1) gene is located on chro- mosome 8p22-23 and functions in several processes proposed to be relevant to pros- tate carcinogenesis. However, the role of MSR in prostate cancer (PCA) progression is unclear. Because PCA usually shows a slowly progressive course, immediate ther- apy might not always be necessary. Previous studies revealed that clinical stage, gleason grade, and serum prostate-speciﬁc antigen (PSA) level were prognostic factors for PCA. However, even with use of these prognostic factors, a decision as to which therapy should be used for PCA can be difﬁcult. Therefore, the discovery of new markers with which to estimate the aggressiveness of PCA is essential to establish appropriate therapeutic modalities. In the present study, the correlation of MSR with recurrence in patients with PCA receiving needle biopsy of the prostate was examined. Methods: MSR was immunohistochemically labeled using a monoclonal (CD204) anti- body. MSR inﬁltration was analyzed in 104 patients ranging from 45 to 88 years (me- dian, 72 years), who received needle biopsy of the prostate. For systematic counting, 6 ocular measuring ﬁelds were randomly cho- sen under a microscope at a power of 400 within a cancer. Results: A signiﬁcant difference was ob- served between lower MSR (26) and higher MSR (26) in Gleason score (p = 0.0016), clinical stage (p = 0.0272), and PSA failure (p = 0.0394). Progression of PCA was found in 26.5% of higher MSR but in 36.4% of lower MSR patients. Recurrence- free survival was signiﬁcantly shorter for patients with lower MSR than those with higher MSR (p = 0.0082). Cox multivariate analysis showed that MSR immunostaining is a prognostic factor for prostate cancer in addition to the clinical stage and Gleason score (p = 0.0349; p = 0.0014; p = 0.0243, respectively). Conclusion: MSR inﬁltration could be a useful prognostic factor in PCA. MP-11.09 Is there a role for digital rectal examination in the diagnosis of prostate cancer in symptomatic men with prostate speciﬁc antigen less than 3ng/ml? Nomikos M, Mariappan P, McNeil A, Bollina PR Department of Urology, Western General Hospital, Edinburgh, U.K. Objectives: Most studies evaluating the di- agnostic role of digital rectal examination (DRE) focus on unselected group of patients that are indented to be representative of the general population. The aim of our study was to evaluate the diagnostic signiﬁcance of an abnormal DRE in a selective group of men presenting with LUTS and PSA less than 3ng/ml. Materials & Methods: Our hospital’s pro- spectively maintained Prostate Biopsy Ser- vice Database of consecutive men undergo- ing prostate biopsies between April 2004 and August 2006 was reviewed. The same experienced urologists performed digital rectal examinations. The association be- tween abnormal DRE and positive prostate biopsy in symptomatic men with PSA less than 3ng/ml was evaluated. Gleason grade, clinical stage and treatments offered were recorded and reviewed. Results: Overall, 1235 men underwent prostate biopsies, of which 59 (4,6%) had PSA3ng/ml and an abnormal DRE. The Positive Predictive Value of an abnormal DRE for detecting prostate cancer in this selective cohort was 25.4%. The incidence of prostate cancer was 13,3%, 33,3% and 53,3% in patients with abnormal DRE and PSA levels of 0.1 to 1.0, 1.1 to 2.0 and 2.1 to 2.9, respectively. Thirteen patients (86,6%) had moderately differentiated dis- ease (Gleason score 6-7). Staging revealed localised, locally advanced and metastatic disease in 11 (73.5%), 3 (20%) and 1 (6.5%) patients, respectively. The majority of patients received radical treatment. Treatment modalities offered were radical prostatectomy, brachytherapy and radical radiotherapy in 2 (13,3%), 5 (33,3%) and 3 (20%) patients, respectively. Hormonal deprivation therapy was offered in 1 pa- tient at the time of presentation. Active monitoring was the treatment of choice in 4 (26,6%) patients. Conclusions: Digital rectal examination has a signiﬁcant value in detecting pros- tate cancer in men presenting with LUTS and low PSA levels. The higher the PSA found the greater the possibility of detect- ing prostate cancer. The majority of can- cers detected by DRE in this selective co- hort were clinically important and potentially curable. MP-11.10 DD3/PCA3 (differential display code 3) in prostate cancer diagnosis – ﬁrst data from Czech Republic Klecka J 1 , Hora M 1 , Pesta M 2 , Holubec L 3 , Topolcan O 2 , Eret V 1 1 Department of Urology, University Teaching Hospital; 2 Central Radioisotope Laboratory of Charles University; 3 De- partment of Oncology, University Teach- ing Hospital, Plzen, Czech Republic Introduction & Objective: Early diagnosis of prostate cancer (PCa) in organ conﬁned stage with following radical treatment are only potential currative approach in PCa. PSA is very helpful in early diagnosis, but the main disadvantage is a low positive pre- dictive value, which results in a high num- ber of uselless biopsies. For that reason we need new tests with better parameters. One promising is PCA3, which is a prostate-spe- ciﬁc non-coding mRNA that is highly over- expressed in prostate tumor cells. One criti- cal factor in developing a clinical procedure is recovering enough prostate cells to ob- tain a valid result. To evaluate diagnostic potential of PCA3 for PCa diagnostic. Methods & Patients: Male urine samples (30-50ml ﬁrst catch) were collected after 30-60 seconds of attentive digital rectal ex- amination (DRE). Urine was kept in refriger- ator and processed within 3 hours with de- tergent based stabilization buffer and frozen at -70°C prior ﬁnal elaboration. Whole urine specimens were from men scheduled for prostate biopsy (n=45) and normals (n=43) from men under 50 years without prostate cancer risk (normal DRE and PSA  1.5 ng/ml). In group of patients with suspicion of PCa we collected one tissue specimen for PCA3 espression in tissue. PCA3 and PSA mRNAs were isolated, ampliﬁed and quantiﬁed using RT PCR method. The PCA3/PSA m RNA ratio distribution was determined for both subject groups. The assess the ability of the PCA3 assay to pre- dict biopsy outcome, the % biopsy positive was determined for different PCA3/PSA ra- tio ranges. Results: In our study, the fraction of speci- mens yielding sufﬁcient RNA for RT PCR MODERATED POSTER SESSIONS 96 UROLOGY 70 (Supplment 3A), September 2007